Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis.
暂无分享，去创建一个
X. Mao | B. Jiang | Xiaohui Duan | Hui Zhang | Lixue Zhou
[1] M. Imamura,et al. Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[2] Ying Cheng,et al. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. , 2019, Translational lung cancer research.
[3] S. Millis,et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma , 2019, Oncotarget.
[4] Gajin Han,et al. Combined Treatment for Lung Metastasis from Hepatocellular Carcinoma: A Case Report , 2018, Explore.
[5] Jianming Xu,et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. , 2018 .
[6] Suzanne F. Jones,et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.